HealthCanal.com Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin. The study used pravastatin-treated patients as the comparison group as pravastatin has been shown ...
Diabetes.co.uk In contrast, the use of fluvastatin and lovastatin was associated with a 5% and 1% decreased diabetes risk, respectively. The researchers concluded: "Clinicians should considers this risk when they are contemplating statin treatment for individual ...
HealthCanal.com Atorvastatin accounted for more than half of all new statin prescriptions followed by rosuvastatin, simvastatin, pravastatin, lovastatin and fluvastatin. The study used pravastatin-treated patients as the comparison group as pravastatin has been shown ...
WebMD Fluvastatin (Lescol) was associated with a 5 percent decreased risk of diabetes and lovastatin (Mevacor) a 1 percent decreased risk. In previous research, Crestor was associated with a 27 percent higher risk of diabetes, while Pravachol was linked to a ...
Highlight Press Statins that were included in the study were lovastatin , pravastatin, fluvastatin, simvastatin, rosuvastatin and atoravastatin. Other studies reveal that though the overall risk for developing a disease like diabetes is low, some patients saw an ...
Medical News Today ... events was highest for atorvastatin (30 outcomes per 1000 person-years) and rosuvastatin (34 per 1000 person-years). Simvastatin made up for 26 outcomes per 1000 person-years with both fluvastatin and lovastatin at 21 outcomes per 100 person-years.
Guardian Express When the FDA approved Lovastatin (Mevacor), the first statin-type cholesterol-lowering drug in 1987, there was great excitement in the healthcare industry because it was perceived as a magic bullet in reducing heart-attack risks. It became the most ...
Hamilton Spectator The researchers said no increased risk was seen with fluvastatin (which is sold under the brand names Lescol, Canef and Vastin) or lovastatin (Mevac...
